We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-28.18%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$553M
AUM Growth
-$476M
Cap. Flow
-$23.2M
Cap. Flow %
-4.2%
Top 10 Hldgs %
90.74%
Holding
22
New
1
Increased
3
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$33M
2
TNGX icon
Tango Therapeutics
TNGX
+$4.79M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$2.94M
4
ANAB icon
AnaptysBio
ANAB
+$1.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$25M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$20.3M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$8.46M
4
UTHR icon
United Therapeutics
UTHR
+$4.39M
5
TECX
Tectonic Therapeutic
TECX
+$1.68M

Sector Composition

Rank Sector Weight
1 Healthcare 98.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ODT
1
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$205M 37.03%
15,238,782
+1,163,513
+8% +$33M
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$355M
$67.8M 12.27%
2,965,485
– –
HRTX icon
3
Heron Therapeutics
HRTX
$86.9M
$42.9M 7.77%
2,896,904
– –
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$38.9M 7.05%
599,091
-381,370
-39% -$25M
ANAB icon
5
AnaptysBio
ANAB
$1.59B
$38.8M 7.02%
2,628,678
+100,000
+4% +$1.8M
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$37.9M 6.86%
9,405,490
+710,016
+8% +$2.94M
BIO icon
7
Bio-Rad Laboratories Class A
BIO
$8.47B
$20.6M 3.73%
40,000
-40,000
-50% -$20.3M
RLMD icon
8
Relmada Therapeutics
RLMD
$546M
$18.8M 3.4%
500,000
– –
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$16.2M 2.92%
160,000
-40,000
-20% -$4.39M
SGMO
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$14.9M 2.7%
1,578,795
– –
PBYI icon
11
Puma Biotechnology
PBYI
$407M
$12.6M 2.27%
1,246,121
-119,255
-9% -$1.21M
CHRS icon
12
Coherus Oncology
CHRS
$225M
$10.1M 1.83%
550,000
– –
TECX
13
Tectonic Therapeutic
TECX
$578M
$9.11M 1.65%
58,333
-8,334
-13% -$1.68M
LSACU
14
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$6.8M 1.23%
500,000
– –
TNGX icon
15
Tango Therapeutics
TNGX
$4.35B
$4.86M 0.88%
+468,750
New +$4.79M
EGRX
16
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.65M 0.48%
62,262
-193,354
-76% -$8.46M
VNDA icon
17
Vanda Pharmaceuticals
VNDA
$314M
$1.85M 0.33%
191,426
– –
PRTA icon
18
Prothena Corp
PRTA
$455M
$1.78M 0.32%
178,688
-95,135
-35% -$1.14M
CTMX icon
19
CytomX Therapeutics
CTMX
$708M
$751K 0.14%
112,880
-187,120
-62% -$1.39M
TENX icon
20
Tenax Therapeutics
TENX
$429M
$708K 0.13%
288
– –
NCNA
21
NuCana
NCNA
$5.24M
– –
-20
Closed -$541K
RDUS
22
DELISTED
Radius Health, Inc.
RDUS
– –
-119,005
Closed -$1.62M

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tang Capital Management held 22 positions worth $553M, down 46% from $1.03B the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Tang Capital Management withdrew a net $23.2M in Q3 2020, closing 2 positions and reducing 8 holdings. Its most notable exit was Radius Health, Inc., an estimated $1.62M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, Tang Capital Management opened a new position in Tango Therapeutics worth $4.86M.

  • Tang Capital Management's largest Q3 2020 buy was Tango Therapeutics: 468,750 shares worth $4.86M.
  • Tang Capital Management added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $33M increase.
  • Tang Capital Management's biggest Q3 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $25M.
  • Tang Capital Management fully exited Radius Health, Inc. in Q3 2020, selling an estimated $1.62M.
  • Tang Capital Management's ten largest holdings make up 91% of its $553M portfolio in Q3 2020.
  • Tang Capital Management opened 1 new position and closed 2 in Q3 2020.
  • Tang Capital Management's portfolio value fell 46% quarter-over-quarter to $553M.

Based on Tang Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.